Our services

ADC Review
is made possible by:




Indusatumab vedotin (MLN-0264) Clinical Trials

Trial Title Study Record Detail Phase Sponsor/Collaborator
A Study of MLN0264 in Patients With Pancreatic Cancer NCT02202785 Phase II Takeda / Millennium Pharmaceuticals, Inc.
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction NCT02202759 Phase II Takeda / Millennium Pharmaceuticals, Inc.
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C NCT01577758 Phase I Takeda / Millennium Pharmaceuticals, Inc.

Indusatumab vedotin is also known as MLN-0264, 5F9vcMMAE, MLN-0264 and MLN0264

Last Editorial Review: July 30, 2016

 

Share

Manuscript Guidelines & Tips

Skip to toolbar